Company 23andMe Holding Co.

Equities

ME

US90138Q1085

Healthcare Facilities & Services

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
0.4709 USD +6.11% Intraday chart for 23andMe Holding Co. -12.52% -48.45%

Business Summary

23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Number of employees: 793

Sales per Business

USD in Million2022Weight2023Weight Delta
Consumer and Research Services
100.0 %
272 100.0 % 299 100.0 % +10.15%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
72.5 %
192 70.8 % 217 72.5 % +12.89%
United Kingdom
21.0 %
58 21.5 % 63 21.0 % +7.77%
Canada
4.5 %
14 5.3 % 14 4.5 % -4.98%
Other Regions
1.9 %
7 2.5 % 6 1.9 % -15.59%

Managers

Managers TitleAgeSince
Founder 50 05-12-31
Director of Finance/CFO 61 22-08-31
Chief Tech/Sci/R&D Officer 53 19-12-31
Chief Tech/Sci/R&D Officer 46 06-12-31
Compliance Officer - 21-07-31
Chief Administrative Officer 60 13-12-31
Chief Tech/Sci/R&D Officer - 21-11-29
Corporate Officer/Principal 43 -
Sales & Marketing - 11-12-31
Human Resources Officer - 17-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 50 21-06-15
Director/Board Member 70 21-06-15
Director/Board Member 50 21-06-15
Director/Board Member 65 21-06-15
Founder 50 05-12-31
Director/Board Member 66 21-11-08
Director/Board Member 50 -
Director/Board Member 62 21-06-20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 167,480,278 167,059,278 ( 99.75 %) 0 96.42 %
Stock B 1 315,436,358 298,562,097 ( 94.65 %) 0

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
7.150 %
22,554,104 7.150 % 13 M $
BlackRock Advisors LLC
6.633 %
20,923,774 6.633 % 12 M $
NewView Capital Management LLC
6.168 %
19,455,681 6.168 % 11 M $
Euclidean Capital LLC
3.247 %
10,243,122 3.247 % 6 M $
Geode Capital Management LLC
2.238 %
7,058,650 2.238 % 4 M $
5,736,198 1.818 % 3 M $
Voya Investment Management Co. LLC
1.749 %
5,517,344 1.749 % 3 M $
Sapphire Ventures LLC
1.678 %
5,291,824 1.678 % 3 M $
Renaissance Technologies LLC
1.103 %
3,478,061 1.103 % 2 M $
3,203,451 1.016 % 2 M $
NameEquities%Valuation
98,633,827 58.53 % 56 M $
GSK PLC
23.53 %
39,660,487 23.53 % 23 M $
1,141,824 0.6775 % 650 840 $
624,136 0.3703 % 355 758 $
Kathy Hibbs
0.0299 %
50,462 0.0299 % 28 763 $

Company contact information

23andMe Holding Co.

349 Oyster Point Boulevard

94080, South San Francisco

+

http://www.23andme.com
address 23andMe Holding Co.(ME)